Arcadia vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Population health and value-based care analytics platform aggregating clinical and claims data for health systems and ACOs. Burlington MA, raised $100M+.
About
Arcadia is a healthcare data and analytics company that helps health systems, ACOs, and payers succeed in value-based care arrangements. Headquartered in Burlington, Massachusetts, and having raised more than $100 million from investors including Andreessen Horowitz, Arcadia's platform aggregates clinical data from EHRs, claims data from payers, and social determinants of health data from community sources into a unified longitudinal patient record. This master data layer powers care management workflows, quality measurement, network analytics, and financial performance reporting for value-based care programs.\n\nArcadia's differentiation lies in its ability to normalize and harmonize data from dozens of disparate EHR and claims sources at scale, giving health system leaders and ACO operators a complete and accurate view of their attributed populations. The platform supports MSSP, Medicare Advantage, commercial value-based contracts, and Medicaid managed care programs, helping organizations track performance against quality metrics like HEDIS and CMS Stars while identifying high-risk members for intervention. Embedded care management tools allow clinical teams to act directly on the insights the platform surfaces.\n\nThe company has positioned itself as a strategic analytics partner for complex, multi-entity health systems that cannot rely on a single EHR vendor for population health insights. Arcadia competes with health IT giants like Health Catalyst and Optum as well as specialty vendors, and has continued to grow its customer base among large regional health systems and national provider organizations participating in risk-bearing contracts.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.